Orifarm Group A/S has announced a pivotal strategic investment from Carlyle’s Global Credit platform, marking a significant step forward in its mission to deliver high-quality, affordable pharmaceuticals across Europe and beyond. The investment, set to close in the fourth quarter of 2024 pending regulatory approval, will fuel Orifarm’s continued expansion and innovation in the healthcare sector.
Founded in 1994 by Hans and Birgitte Bøgh-Sørensen, Orifarm has grown into a dynamic, family-owned healthcare company with a robust international footprint. Despite this new partnership, Orifarm will remain privately held by the founding family, preserving its core values and entrepreneurial spirit.
Chairman and founder Hans Bøgh-Sørensen expressed pride in the company’s journey and enthusiasm for the road ahead. “For over three decades, we’ve built Orifarm with a clear purpose—making medicine more accessible. With Carlyle’s support, we’re strengthening that purpose while maintaining our independence and integrity.”
CEO Erik Sandberg emphasized the investment’s impact on strategic initiatives, referencing Orifarm’s transformational acquisition from Takeda in 2020 as a foundation for this next growth phase. The capital will enable Orifarm to pursue both organic and inorganic opportunities across its Pharma Trade, Specialty Rx, and Consumer Healthcare segments.
Carlyle’s Nicola Falcinelli praised Orifarm’s commitment to quality and accessibility, highlighting the firm’s excitement in supporting a visionary, multi-generational business. The terms of the transaction remain confidential, but its significance for the future of affordable healthcare in Europe is clear.